Akron, United States
Elysium's O2P™ (Oral Overdose Protection) platform seeks to limit exposure to active opioids and prevent overdose. The XpiRx™ (Forced Expiration) aims to reduce abuse and prevent fatal overdoses by creating opioids with a shorter half-life. Additionally, SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) offers longer-acting and more effective rescue against synthetic opioids.
Founded in 2013, Elysium has showcased high-probability of success with proof-of-concept data and has leveraged approximately $16M in non-dilutive grant funding. The company's diversified portfolio of programs addresses key factors driving the opioid crisis and could yield multiple products within 3-5 years. Elysium holds strong intellectual property protection and has issued patents in the US and internationally, including composition of matter. The last investment was a Private Equity Round in 31 March 2019, led by Tech Coast Angels.
Elysium's innovative solutions, market potential, and promising risk/reward profile make it a compelling investment opportunity.
